Abstract
UCBT offers a cure for thalassemia and CB has advantages as a stem cell source for minorities, where thalassemia is prevalent. Previously mortality risks outweigh benefits and cell dose is critical for UCBT. With strategies that maximize cell dose - using non-red cell reduced plasma depleted (PD) CB, no post-thaw wash (NW), and double cord transplantation (DCT), promising results may be achieved with UCBT in selected thalassemics. Between 7/01 and 9/06, 47 UCBT were performed after myeloablative therapy in 41 pediatric patients with thalassemia major (7 DCT & 1 re-transplant) at 14 transplant centers (TC) using 81% PD CB with 91% NW.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
